Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.

ABSTRACT:

Background

Severe asthma is a major cause of morbidity. Some patients may benefit from biological therapies. Most evaluations of these treatments are derived from randomized controlled trials (RCTs), but few patients are eligible for these trials. Studies involving more diverse groups of participants exist, but there is a lack of precise pooled estimates.

Objective

This systematic review aims to evaluate the real-world efficacy of recently and nearly licensed biological therapies for severe asthma to assess the generalizability of the RCT data.

Methods

Clinical outcomes including exacerbation rate, oral corticosteroid usage, forced expiratory volume in 1 second (FEV₁ ) and fractional exhaled nitric oxide (FeNO) were examined. Studies were assessed for risk

SUBMITTER: Charles D 

PROVIDER: S-EPMC9311192 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature